Research

Hormonal

Semaglutide, a GLP-1 receptor agonist, produces significant weight loss (up to 15.8% at 68 weeks) and improves cardiovascular outcomes in patients with obesity or type 2 diabetes.

Semaglutide is a highly effective weekly injection for obesity and type 2 diabetes, achieving nearly 15% weight loss in clinical trials. It works by mimicking the GLP-1 hormone, which regulates hunger and digestion. It also offers cardiovascular benefits, reducing the risk of heart attack and stroke.

StrongSupportsHIGH confidence
The STEP 1 randomized controlled trial investigated semaglutide 2.4 mg weekly and found a body weight loss of −14.9% vs −2.4% with placebo at 68 weeks.
Thomas W. Fredrick et al. · Clinical Pharmacology Advances and Applications · 2025

Why this rating

Supported by Phase 3 trials (STEP 1-5, SELECT).

Source

Pharmacotherapy for Obesity: Recent Updates

Thomas W. Fredrick et al. · Clinical Pharmacology Advances and Applications · 2025

DOI 10.2147/cpaa.s497904

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →